Saturday 17 October 2026 Export NYXH’s income statement to Excel — free account

Nyxoah SA

NYXH Healthcare Medical Instruments & Supplies

Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024. In the quarter to June 2026, revenue grew 486.6%, EPS fell 6.35%, free cash flow grew 4.01% and total debt rose 185.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

1.11 0.08 −6.72%

Follow NYXH

Alert me

Market cap: $121.2M
P/E: 0.0×
Fwd P/E: −1.7×
Dividend yield: —
F-score: 3/9
Altman Z: −4.39
Beneish M: −2.78
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 121.19

Revenue 25.08

Net Income (108.29)

Free Cash Flow (86.51)

Net Debt (44.59)

Current Ratio 2.38

Debt/Equity 0.72

P/E ratio 0.00

Fwd P/E (1.68)

P/S ratio 2.52

P/B ratio 0.65

Past 5Y EPS Growth —

This Y EPS Growth 52.61%

Next Y EPS Growth 37.71%

Next Y revenue growth 273.36%

Next 5Y EPS Growth 42.94%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.09%

10-year low 10-year high

P/B against its own 10 years 0.07%

10-year low 10-year high

EV/Sales against its own 10 years 0.09%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	63	93	54	114
Receivables	6	7	8	12
Inventory	4	5	5	4
Other	1	2	1	1
	74	106	69	131

	2023	2024	2025	Q'26
Payables	7	10	16	15
ST’ Debt	0	0	26	27
Other	—	7	9	8
	16	23	55	55

Compound Annual Growth %

	10y	5y	3y
Sales	—	170.14%	51.67%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(12.92%)	(24.03%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	7	9	—	—	—
’25	1	2	2	7	11
’24	1	1	1	1	5
’23	0	1	1	2	5
’22	1	1	0	1	3
’21	0	0	0	—	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(25)	(19)	—	—	—
’25	(20)	(21)	(21)	(17)	(78)
’24	(13)	(12)	(15)	(13)	(53)
’23	(11)	(13)	(12)	(12)	(48)
’22	(6)	(4)	(8)	(12)	(30)
’21	(5)	(5)	(11)	—	(30)
’20	—	—	—	(8)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(21)	—	—	—
’25	(21)	(22)	(21)	(18)	(82)
’24	(16)	(13)	(16)	(14)	(60)
’23	(15)	(16)	(15)	(14)	(60)
’22	(10)	(9)	(12)	(17)	(48)
’21	(7)	(8)	(11)	—	(44)
’20	—	—	—	(9)	(20)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.43)	(0.67)	—	—	—
’25	(0.63)	(0.63)	(0.74)	(0.68)	(2.67)
’24	(0.45)	(0.46)	(0.55)	(0.49)	(1.96)
’23	(0.49)	(0.49)	(0.29)	(0.41)	(1.67)
’22	(0.29)	(0.21)	(0.24)	(0.52)	(1.27)
’21	(0.31)	(0.37)	(0.41)	—	(1.37)
’20	—	—	—	—	(0.77)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	19.05	4.70	4.36	4.00	4.35	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	37.00	23.05	10.34	20.00	11.87
People
People	Employees	—	—	—	—	78	103	138	147	184	154
	Revenue/emp, $m	—	—	—	—	0.00	0.01	0.02	0.03	0.03	0.07
Income, $m
Income, $m	Revenue	—	—	—	—	0	1	3	5	5	11
	Gross margin, %	—	0.00	0.00	0.00	56.47	64.43	62.71	61.92	65.67	63.13
	EBT	—	(12)	(10)	(9)	(14)	(29)	(32)	(48)	(61)	(101)
	EBT margin, %	—	0.00	0.00	0.00	(17,615.74)	(2,891.90)	(974.58)	(1,027.08)	(1,248.21)	(888.98)
	Net income	—	0	(10)	(9)	(14)	(29)	(32)	(48)	(61)	(101)
	Depreciation	—	0	0	0	1	2	2	3	3	5
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.04	0.13	0.17	0.15	0.30
	Earnings	—	(0.58)	(0.48)	(0.44)	(0.77)	(1.37)	(1.27)	(1.67)	(1.96)	(2.67)
	Cash flow	—	(0.47)	(0.44)	(0.31)	(0.44)	(1.26)	(1.17)	(1.73)	(1.63)	(2.05)
	Capex	—	0.00	0.00	0.00	(0.67)	(0.59)	(0.67)	(0.42)	(0.20)	(0.11)
	Free cash flow	—	(0.47)	(0.44)	(0.31)	(1.12)	(1.85)	(1.84)	(2.16)	(1.83)	(2.16)
	Book value	—	0.25	0.56	0.12	6.13	7.39	4.91	3.79	3.74	1.46
	Shares, m	—	21	21	21	18	24	26	28	33	38
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	0.00	42.03	28.11	53.54	15.46
	P/B	—	—	—	—	4.81	5.65	1.08	1.25	2.14	3.15
	EV/Sales	—	—	—	—	0.00	0.00	14.90	17.56	39.38	14.79
	EV/FCF	—	—	—	—	0.00	(16.95)	(1.02)	(1.37)	(3.22)	(2.04)
Cash, $m
Cash, $m	Operating cash flow	—	(10)	(9)	(7)	(8)	(30)	(30)	(48)	(53)	(78)
	Capex	—	0	0	(6)	(12)	(14)	(17)	(12)	(7)	(4)
	Free cash flow	—	(10)	(9)	(7)	(20)	(44)	(48)	(60)	(60)	(82)
Balance, $m
Balance, $m	Working capital	—	11	18	4	100	152	90	58	83	14
	Total debt	—	6	7	10	13	13	12	13	23	47
	Net debt	—	(6)	(13)	3	(93)	(147)	(88)	(50)	(69)	(8)
	Shareholders’ equity	—	5	12	3	111	176	127	106	123	56
Returns, %
Returns, %	ROA	—	(73.30)	(101.00)	(50.34)	(18.98)	(19.66)	(18.48)	(32.45)	(41.92)	(66.74)
	ROIC	—	0.00	0.00	0.00	(43.96)	(67.76)	(55.45)	(54.08)	(74.65)	(122.99)
	ROE	—	(143.04)	(119.47)	(129.51)	(24.61)	(22.78)	(21.74)	(40.17)	(56.07)	(114.43)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OSUR OraSure Technologies, Inc.	$262.8M	— (loss-making)	— (loss-making)	−1.93% (below 0%: shrinking)	n/m	−1.40% (below 0%: shrinking)	43.46%	17.76%	Compare
UTMD Utah Medical Products, Inc.	$237.8M	22.7×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%	Compare
PDEX Pro-Dex, Inc.	$194.1M	13.8×	23.5×	+16.65% (above 0%: growing)	+143.24% (above 0%: growing)	−78.95% (below 0%: shrinking)	34.75%	17.29%	Compare
KRMD KORU Medical Systems, Inc.	$139.9M	— (loss-making)	— (loss-making)	+18.15% (above 0%: growing)	n/m	+26.17% (above 0%: growing)	65.14%	5.21%	Compare
NYXH Nyxoah SA	$121.2M	— (loss-making)	— (loss-making)	+486.62% (above 0%: growing)	n/m	+4.01% (above 0%: growing)	59.73%	(268.25%)
STXS Stereotaxis Inc.	$105.2M	— (loss-making)	— (loss-making)	−12.82% (below 0%: shrinking)	n/m	+0.45% (above 0%: growing)	58.49%	(59.56%)	Compare
MBOT Microbot Medical Inc.	$63.8M	— (loss-making)	—	+1,047.62% (above 0%: growing)	n/m	−98.72% (below 0%: shrinking)	(266.80%)	(2,567.63%)	Compare
ZTEKF Zentek Ltd.	$62.3M	— (loss-making)	—	−95.36% (below 0%: shrinking)	n/m	−254.61% (below 0%: shrinking)	0.00%	0.00%	Compare
DXR Daxor Corporation	$59.6M	4.7×	7.6×	−27.62% (below 0%: shrinking)	n/m	−88.56% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$122.6M	13.8×	23.5×	−7.38%	—	−67.34%	39.11%	2.61%

All 55 Medical Instruments & Supplies stocks →

Nyxoah SA (NYXH) key facts

Strength: Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024.
Nyxoah SA (NYXH) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NYXH traded at $1.11, a market capitalization of $121.2 million.
Return on equity was −114.4% and debt-to-equity 0.72.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −4.39 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.